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BIOTECHNOLOGY PATENT LAW: PERSPECTIVE OF THE




The era of biotechnology began in 1973 when Stanley N. Cohen
and Herbert W. Boyer reported that a gene could be cut from the DNA
of one organism, recombined in vitro with DNA of a host organism, and
re-introduced into cells of the host to confer the gene's characteristic
trait to the host.' The industry which sprang up to exploit the potential
of Cohen and Boyer's recombinant DNA technology has now existed for
seventeen years-the lifetime of a United States patent. 2 In the world of
patent practice this year constitutes a divide, a point when it is appropri-
ate to take stock of the legal developments of the preceding patent life-
time and to consider what may be in store for practitioners in the next
seventeen years.
This article is divided into two sections. The first provides an his-
torical perspective of the first seventeen years of biotechnology patent
law. The second section examines some current trends and how they
may affect the development of the law over the next seventeen years.
II. HISTORICAL PERSPECTIVE
A. Public Apprehension
Biotechnology grew up under a floodlight of intense public scrutiny
and debate. Many of the new companies formed to exploit the commer-
cial potential of the scientific advances of the preceding two decades
generated publicity to aid in attracting investors. Scientists publicly de-
bated their concerns about the possible hazards or disastrous conse-
quences of certain types of experiments. Some feared the possible
creation of new pathogens which, if improperly contained, could spread
into the environment.
In response to the concerns, the National Institutes of Health
promulgated guidelines for conducting recombinant DNA research.
* President, Greenlee and Associates, P.C., Boulder, CO; Ph.D., Duke University,
1962; J.D., University of Utah College of Law, 1976; Research Fellow, Duke University,
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1. See Cohen & Boyer, Construction of Biologically Functional Bacterial Plasmids in Vitro, 70
PRoc. NAT'L ACAD. Sci. 3240 (1973)[hereinafter Cohen & Boyer]. The following United
States patents have issued to Cohen and Boyer on their "biologically functional molecular
chimeras": U.S. Patent No. 4,237,224, issued December 2, 1980; U.S. Patent No.
4,468,464, issued August 28, 1984; and U.S. Patent No. 4,740,470, issued April 26, 1988.
2. 35 U.S.C. § 154 (1988)(patent term is seventeen years).
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Subsequently, these guidelines underwent a series of revisions that re-
sulted in an increased number and scope of allowable activities. The
revisions were a result of improved understanding of the actual risks
involved from working with genetically engineered microorganisms.
3
Today, risks from "recombinant DNA" research are considered to be
much lower than originally estimated, and more specifically defined.
4
B. Patentability of Living Matter
The issues of patentability that first confronted patent practitioners
were more pedestrian, but acquired a certain cachet in the light of the
intense public interest in the safety and morality debates. Whether a
living organism was patentable subject matter under section 101 of the
Patent Act 5 was a prominent issue. The Patent and Trademark Office
(Patent Office) rejected two applications claiming a microorganism per
se as if it were a device or a composition of matter.6 The Court of Cus-
toms and Patent Appeals 7 held that the microorganisms were patentable
subject matter.8 The United States Supreme Court reviewed the lower
courts' decisions and held that an invention was not unpatentable
merely because it was alive. 9 The Supreme Court stated that the range
of the patent laws was intended to encompass "anything under the sun
that is made by man." 1 0 The Court, however, did not specify in which
3. Guidelines for Research Involving Recombinant DNA Molecules, 51 Fed. Reg. 16,958
(1986)(listing the most current version of the guidelines). The National Institutes of
Health is the major funding agency for biomedical research.
4. See ORGANIZATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT, RECOMBI-
NANT DNA SAFETY CONSIDERATIONS (1986):
Concern has been expressed that application of... rDNA organisms in the envi-
ronment may present ecological risks, and attempts have been made to evaluate
this potential for harm.... Past experience with species introduction have been
studied in attempts to establish possible risks. In the great majority of instances
no adverse consequences were noted.
Id at 28.
5. Section 101 of the Patent Act provides that:
Whoever invents or discovers any new and useful process, machine, manufacture,
or composition of matter, or any new and useful improvement thereof, may ob-
tain a patent therefor, subject to the conditions and requirements of this title.
35 U.S.C. § 101 (1988).
6. The Patent Office rejected the application of Malcolm E. Bergy for a biologically
pure culture of the microorganism streptomyces vellosus. In re Bergy, 596 F.2d 952, 971
(C.C.P.A. 1979), vacated as to Bergy sub nom. Diamond v. Bergy, 444 U.S. 1028 (1980), aff'd
sub nom. Diamond v. Chakrabarty, 447 U.S. 303 (1980). The Patent Office similarly re-
jected the application of Amanda M. Chakrabarty for a novel strain of oil-degrading
Psuedomonas. Id. at 971.
7. Appellate jurisdiction for patent matters now resides in the United States Court of
Appeals for the Federal Circuit. Federal Courts Improvement Act of 1982, Pub. L. No. 97-
164, § 127(a), 96 Stat. 37 (codified as amended at 28 U.S.C. § 1295 (1988)).
8. In re Bergy, 596 F.2d at 973.
9. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
10. Id. at 309 (citing S. REP. No. 1979, 82d Cong., 2d Sess. 5 (1952); H.R. REP. No.
1923, 82d Cong., 2d Sess. 6 (1952)). The same language was used in testimony by PJ.
Federico regarding the 1952 Patent Act recodification legislation. Id. at 309 n.6. See also,




category under section 101 microorganisms belonged." This exercise
of judicial restraint may ultimately prove most wise.
It is no coincidence that the patentability of living matter became an
issue when it did. Microorganisms were in common use for producing
antibiotics by fermentation since the 1950s. Patents for methods of syn-
thesis using a specified microorganism strain were not uncommon. Vac-
cines made using microorganisms or containing killed or attenuated
microorganisms were also the subject of patents. In fact, patents to
organisms per se had already been granted.1 2 The concept that the
property of being alive could constitute a bar to patentability gained no-
toriety concurrently with the extensive public debate on the hazards of
recombinant DNA and genetic engineering. The politics of the times
generated this issue, abetted by misperceptions of the chemical and
physical underpinnings of biological science. As one amicus curiae to
the Chakrabarty Court pointed out, the issue before the Court consti-
tuted yet another last gasp of the vitalistic fallacy.) 3 When viewed in this
light, it is not only remarkable that the patentability of living matter be-
came an issue, but also remarkable that the Supreme Court agreed to
decide it.
Other cases interpreting the scope of patentable subject matter
under section 101 in the context of other technologies also affected bio-
technology patent law. In particular, Parker v. Flook 14 and several cases
involving geophysical prospecting' 5 dealt with inventions using infor-
mation in the form of programs, algorithms, read-only memories, and
other embodiments of information in combination with other process
steps. DNA is a molecule that embodies genetic information, a read-
only memory for programming biological systems. Consequently, the
approaches taken in these cases also ultimately affected the direction of
biotechnology patent law.
C. Products of Nature
Advances in biotechnology have also forced closer scrutiny of the
"product of nature" rule. Statements in court opinions, often dicta, un-
supported by statutory reference have fostered the misconception that
all naturally occurring materials are unpatentable subject matter. The
11. 447 U.S. at 318. The categories under 35 U.S.C. § 101 include process, machine,
manufacture, and composition of matter.
12. In a foresighted review, Edward S. Irons and Mary Helen Sears showed that the
patentability of microorganisms was never questioned prior to the 1970s, despite numer-
ous opportunities to do so. Irons & Sears, Patents in Relation to Microbiology, 29 ANN. REv.
MICROBIOLOGY 319 (1975).
13. Brief for Dr. George Pieczenik as Amicus Curiae at 3-4, Diamond v. Chakrabarty,
447 U.S. 303 (1980)(No. 79-136). "To attempt to separate patentable and unpatentable
subject matter on the basis of [living matter and non-living matter] is to invite confusion in
the art, to ignore existing law and to ignore scientific reality." Id. at 3-4 (citations
omitted).
14. 437 U.S. 584 (1978).
15. In re Sherwood, 613 F.2d 809 (C.C.P.A. 1980); In re Freeman, 573 F.2d 1237
(C.C.P.A. 1978); In reJohnson, 589 F.2d 1070 (C.C.P.A. 1978); In re Abrams, 188 F.2d 165
(C.C.P.A. 1951).
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underlying policy is that what exists in nature is part of the public do-
main and therefore freely available to all.' 6 In expressing the rule thus,
the statutory underpinning for this argument would seem to be section
10117 or section 102 of the Patent Act.18 When the very existence of a
natural compound is unknown before the inventor's activities, however,
it strains logic to characterize the compound as not new or lacking nov-
elty. Courts, persuaded by evidence of the technical value added by the
inventor's activities, have held materials isolated and purified from na-
ture patentable. 19 When human intervention has so altered the natural
material from its natural state as to make it more useful, or useful in new
ways, or cheaper, or available in greater quantity, the result is an addi-
tion to value over the natural state that merits patent protection. View-
ing the natural state as prior art, the analysis of patentability of products
of nature most logically proceeds under section 103.20
Many of the inventions in biotechnology involve materials purified
from nature or otherwise manipulated from their natural state. Thus the
cases interpreting the "product of nature rule" as an aspect of unobvi-
ousness have facilitated patent protection for biotechnology most signif-
icantly. As long as the fundamental criteria set forth in Graham v. John
Deere21 are met, valid claims to compounds isolated from a natural
16. See, e.g., General Elec. Co. v. De Forest Radio Co., 28 F.2d 641, 642 (3d Cir.
1928), cert. denied, 278 U.S. 656 (1929)
If it is a natural thing then clearly, even if [the patentee] was the first to uncover it
and bring it into view, he cannot have a patent for it because a patent cannot be
awarded for a discovery or for a product of nature, or for a chemical element.
(citing United States Indus. Chem. Co. v. Theroz Co., 25 F.2d 387 (4th Cir. 1928);
Anheuser-Busch Ass'n v. United States, 207 U.S. 556, 562 (1908) (cork, without "having a
distinctive name, character or use" held unpatentable)(citation omitted); Hartranft v.
Wiegmann, 121 U.S. 609, 615 (1887)(shells that have not been manufactured into a new
and different article held unpatentable).
17. 35 U.S.C. § 101 (product of nature is not "new").
18. 35 U.S.C. § 102 provides in part that a person shall be entitled to a patent unless:
(a) the invention was known or used by others in this country, or patented or
described in a printed publication in this or a foreign country, before the inven-
tion thereof by the applicant for patent, or
(b) the invention was patented or described in a printed publication in this or a
foreign country or in public use or on sale in this country, more than one year
prior to the date of the application for patent in the United States ....
35 U.S.C. § 102 (1988).
19. See, e.g., In re Bergy, 596 F.2d 952 (C.C.P.A. 1979), vacated as to Bergy sub nom.
Diamond v. Bergy, 444 U.S. 1028 (1980), aff'd sub nom. Diamond v. Chakrabarty, 447 U.S.
303 (1980); In re Bergstrom, 427 F.2d 1394 (C.C.P.A. 1970); Merck & Co. v. Olin Mathie-
son Chem. Corp., 253 F.2d 156, 164 (4th Cir. 1958)(Compositions of "great therapeutic
and commercial worth" are patentable where they are purifications of naturally occuring
fermentates.).
20. Section 103 mandates that a patent be denied where:
mhe differences between the subject matter sought to be patented and the prior
art are such that the subject matter as a whole would have been obvious at the
time the invention was made to a person having ordinary skill in the art to which
said subject matter pertains.
35 U.S.C. § 103 (1988).
21. 383 U.S. I (1966). According to the Court in Graham, an analysis of obviousness
under section 103 must be based on several factual inquiries: (1) the scope and content of
the prior art; (2) the differences between the prior art and the claims at issue; (3) the level
of ordinary skill in the art at the time the invention was made; and (4) objective evidence of
nonobviousness, if any. Id. at 17-18.
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source, such as biological material, can be obtained. Examples of pat-
entable products include cloned genes, DNA segments recombined in
novel combinations, novel organisms possessing heterologous DNA, mi-
croorganisms isolated from natural sources, and purified proteins.
D. Novelty
Although biotechnology has experienced rapid and expansive pro-
gress, the field could not be characterized as crowded. Issues of antici-
pation under section 10222 have not been encountered with great
frequency. Those items which have been confronted could be catego-
rized as matters of interpretation. Scripps Clinic & Research Foundation,
Inc. v. Genentech, Inc.2 3 suggests that a protein synthesized by recombi-
nant means is anticipated by the naturally occurring protein in purified
form. Patent examiners occasionally consider whether an unpurified
mixture of DNA fragments sorted into vectors (a genomic or cDNA li-
brary24 ) anticipates a cloned gene. The rationale behind this is uncer-
tain, since pure compounds are not deemed anticipated by impure
mixtures. 25 Similar to the product of nature rule, such situations are
best analyzed by determining how obvious the cloned gene would be to
one skilled in the art, given knowledge of the library.
E. Obviousness
Due to the pioneering nature of many biotechnology inventions
during the first seventeen years, issues of obviousness under section 103
have not been fully explored. The chemical structures of nucleic acids
and proteins are so similar to one another that standard chemical analy-
sis of monomer composition, molecular weight, viscosity and the like
would lead to a conclusion of obviousness on structural criteria alone.
Details of the sequences of nucleotides or of amino acids are the struc-
tural features that distinguish one nucleic acid or protein from another.
The crucial distinguishing features are functional: how the compounds
behave in biological systems, or how the compounds affect the behavior
of biological systems themselves. Consequently, where sequence is an
element of the disclosure, its main value, beyond proving novelty, is to
help satisfy disclosure requirements. 26 No comprehensive theory relat-
ing chemical structure to biological function yet exists. Thus, if a bio-
chemist develops a composition with novel structure and unobvious
function, the Patent Office might consider the cloned DNA or purified
22. 35 U.S.C. § 102.
23. 666 F. Supp. 1379 (N.D. Gal. 1987).
24. For a definition ofa genome and references that discuss genomic or cDNA librar-
ies see infra note 49.
25. See, e.g., In re Bergstrom, 427 F.2d at 1401-02 ("[B]y definition, pure materials
necessarily differ from Less pure or impure materials and, if the latter are the only ones
existing and available as a standard of reference... perforce the 'pure' materials are 'new'
with respect to them.")(citation omitted); In re Gofer, 354 F.2d 664 (C.G.P.A. 1966); In re
Seaborg, 328 F.2d 996 (C.C.P.A. 1964).
26. See infra note 34 and accompanying text.
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protein unobvious. When the composition possesses a structure (se-
quence) similar to that possessed by a prior art compound and no new
function or unobvious property can be shown, the standard of section
103 may not be met.
2 7
Together, the recent cases of In re Durden
2 8 and In re Pleuddemann2 9
have cast doubt on the unobviousness of processes where the only novel
and unobvious element is the starting material. These cases do not ex-
pressly overrule prior cases that reached a contrary result,8° making it
unclear if a principle of law can be extracted from them. Many biotech-
nology process inventions could be affected by these decisions. Current
efforts to clarify the situation by legislation are discussed elsewhere in
this issue.
3 l
Despite the fact that many biotechnology inventions could be con-
sidered pioneering, the "obvious to try" issue has been frequently
raised, partly, because much of the prior art has been published aca-
demic work. In re O'Farrell3 2 clarified the line between what is merely
obvious to try and what is obvious. The applicants' published prelimi-
nary result was effective prior art against their own application. The
claimed result was correct expression of a foreign gene in a recombinant
host cell. The preliminary result was synthesis of an uncharacterized,
high molecular weight protein using as the foreign "gene" a segment of
DNA not known to encode a protein. In finding the invention obvious
over the prior art, the court stated that "[o]bviousness does not require
absolute predictability of success." 3 3 This case suggests that one
crosses the line from "obvious to try" to "obvious" when the prior art
discloses a crude version of the end result.
F. Description and Enablement
A variety of issues have arisen in the biotechnology art regarding
description and enablement under section 112 of the Patent Act.
3 4
Many fall into the category of adequacy to support desired claim
breadth, while others fall into the category of deposits of living organ-
27. For a discussion of the historical development of the obviousness question in
chemical patents, how similarity in structure between a new compound and prior art leads
to a pnma facie case of obviousness, and how the current views of the Federal Circuit on
this subject may impact the biotechnology field see Wall & Dituri, The En Banc Rehearing of
In re Dllon: Policy Considerations and Implications For Patent Prosecution, 68 DEN. U.L. REv. 261
(1991) [hereinafter Wall & Dituri].
28. 763 F.2d 1406 (Fed. Cir. 1985).
29. 910 F.2d 823 (Fed. Cir. 1990).
30. See, e.g., In re Mancy, 499 F.2d 1289 (C.C.P.A. 1974).
31. Baechtold, Property Rights in Living Matter: Is New Law Required?, 68 DEN. U.L. REv.
141 (1991); Beir & Bensen, Biotechnology Patent Protection Act, 68 DEN. U.L. REv. 173 (1991).
32. 853 F.2d 894 (Fed. Cir. 1988).
33. Id. at 903.
34. To obtain a valid patent on a new, useful, and nonobvious invention, the patent
applicant must file a specification fully disclosing the invention and how to make and use
it. 35 U.S.C. § 112 (1982). Section 112 requires that the applicant describe three items:
(1) the invention (the description requirement); (2) the manner and process of making and
using the invention (the enablement requirement); and (3) the best mode contemplated by
the inventor of carrying out his invention (the best mode requirement).
[Vol. 68:2
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isms. The initial success of Cohen and Boyer in obtaining broad patent
protection for a process that is the basic tool of the industry encouraged
other pioneers in the field to hope for similar broad coverage. For a
time, researchers feared that a number of broad blocking patents could
limit opportunities for later entrants into the field. As the industry has
grown, however, it now appears that problems of securing adequate
claim breadth are more likely to be encountered.
Biotechnology is a field where functionally equivalent -variants
abound. Despite the fact that at critical loci a single base change in a
nucleic acid sequence or a single amino acid substitution in a protein
can drastically alter function, many non-critical loci occur which tolerate
all sorts of sequence variations without affecting function. A claim lim-
ited to one sequence, or even half a dozen functionally equivalent se-
quence variants, is virtually worthless if a competitor can simply make
another functional variant outside the claim. Given that literally
thousands of functionally equivalent sequence variants exist, and that
defining each of them is an impossible task (and useless since no new
function is achieved thereby), practitioners have resorted to claiming a
combination of sequence and function to obtain adequate claim cover-
age. Such claims, while they purport to be drawn to a family of com-
pounds, take on the character of mechanical claims having means plus
function language.3 5 The case law relevant to the field of biotechnology
is not limited to the field of chemical practice. Until the field develops
its own body of precedents, precedents from other arts will be
influential.
G. Organism Deposits
The practice of depositing a sample of a living organism in a public
depository in order to comply with the requirements of section 11236 is
peculiar to biotechnology. This practice originated with making volun-
tary deposits to support process claims that used a specific novel micro-
organism strain. The deposit of the organism supplemented the written
disclosure, where the specification could not describe how to make and
use the microorganism.3 7 In the late 1970s to mid-1980s, deposits were
used extensively throughout the world.38 With the Budapest Treaty,
3 9
an applicant could make a single deposit to satisfy the deposit require-
35. Adequate support for such claims must include teaching how to make and use
functionally equivalent variants. Amgen, Inc. v. Chugai Pharmaceutical Co., Nos. 90-1273,
-1275 (Fed. Cir. Mar. 5, 1991) (LEXIS, Genfed library, U.S. App. file 3481; WESTLAW,
CTAF database 27262), aff'g in part, rev'g in part, vacating in part 13 U.S.P.Q.2d (BNA) 1737
(D. Mass. 1989).
36. 35 U.S.C. § 112.
37. In re Argoudelis, 434 F.2d 1390 (C.C.P.A. 1970).
38. See Winner & Denberg, Requirements For Deposits of Biological Materials For Patents
World Wide, 68 DEN. U.L. REv. discussing (1991)[hereinafter Denberg & Winner](deposit
requirements in various countries).
39. Budapest Treaty on the International Recognition of the Deposit of Micro-
organisms for the Purposes of Patent Procedure, April 28, 1977, 32 U.S.T. 1243, T.I.A.S.
No. 9768, 17 I.L.M. 285.
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ment for any signatory country where the applicant's case was filed. The
United States promulgated rules governing deposit practice in 1989.40
Upon issuance or publication, deposited materials must be available
to the public. Applicants who are bound by this requirement do not
favor it. For those who wish to enter the field, however, the deposit
system is a boon, since they can avail themselves of the claimed organ-
isms. The direct public access to the invention is unique to biotechnol-
ogy. In other fields, public disclosure merely provides a set of
instructions enabling competitors to reproduce the invention. Access to
a deposited organism, however, short-cuts the need for sufficient skill to
make the invention. The end product is placed directly into the hands
of would-be competitors. Furthermore, such access is granted to any-
one, even those not subject to United States law. The net effect is to
encourage copying and counterfeiting. An applicant who must deposit
materials to comply with section 112 has very little protection against
such copying, short of infringement litigation. 4 1 Applicants who wish to
avoid deposits must resort to trade secrets or provide a written disclo-
sure teaching how to make the claimed organism from publicly available
precursors. Lack of consistent standards among countries as to why a




A serious threat is presented by the infrastructural problems within
the Patent Office. A recent report from the General Accounting Office
stated that the backlog of biotechnology applications swelled by twenty-
seven percent, from 6200 inJanuary, 1989, to 7914 in May, 1989. 4 3 As
a result, long delays occur, often as long as seven years, from the filing
date to the issue date.4 4 Despite the promulgation of new rules in-
tended to resolve interferences within two years, cases are frequently
suspended from prosecution for more than six months before an interfer-
ence is declared. Litigants must frequently wait a year for decisions on
preliminary motions.
Prosecution delays create incalculable consequences for the indus-
try. As long as ownership rights remain unclear, companies continue to
invest in research and development, and to introduce new products. By
the time the patents issue, products are already in the market and litiga-
tion may be the only recourse. Litigation, interferences and even pro-
tracted prosecution are serious economic burdens, especially for small
40. 37 C.F.R. §§ 1.801-1.809 (1989).
41. The American Type Culture Collection will provide, for an additional fee, names
of persons who have accessed the deposit. The applicant then has a basis for taking action
against any infringer foolish enough to access the deposit in his own name.
42. See generally Denberg & Winner, supra note 38.
43. Andrews, Long Delay Seen in Patents for Genetic Engineering, N.Y. Times, July 19,
1990, at Dl.
44. See Cohen & Boyer supra note 1. The parent Cohen-Boyer patent, for example,
was pending for seven years before the first claim issued.
[Vol. 68:2
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companies. Because most innovation takes place in smaller companies,
the ultimate effect of the exaggerated costs and economic burden of
procuring and enforcing patent protection is to stifle innovation rather
than to promote it.
III. PROSPECTIVE VIEW
Turning to the next seventeen years, what trends can be projected




Several recent developments in the biological sciences suggest new
directions that may expand the scope of biotechnology. Recently, sev-
eral papers have been published describing processes that open the
door for new "biological" materials that have no counterpart in living
organisms.4 6 Novel proteins and nucleic acids can be developed by a
combination of selection methods and specific amplification methods
that yield molecules having a desired function. The ability to generate
an endless number of new functions using variants of a single method
will further emphasize the differences in rationale between chemical and
biotechnology patent practice.
The technologies of the foregoing type will include a basic set of
steps, modified only by varying a selection step. The starting material is
the same-a pool of randomized sequences from which one having the
desiredfunction is ultimately isolated. Structure will not be predictable,
however, the selected structure will be one of those present in the start-
ing mixture. The method can isolate other structures having the same
function, but those may have different sequences. While the structures
would be patentable under conventional analysis as an unpredictable
structure, once a technique for isolating structures having a particular
function is known, other compounds with the same (equivalent) function
can be generated. Techniques of this sort inherently possess means for
generating a compound having a function. Similar to nonchemical in-
ventions, such processes shift the emphasis from the structure of the
resulting compound (sequence of amino acids or nucleotides), to its
function. The same situation is reflected in existing technology where
alternative functional sequences abound. The technological trend
45. No one understands better than a patent attorney the cruel disjunction of fore-
sight and hindsight. That which is crystal clear after the fact is shrouded in fog before-
hand. The following is offered with a painful sense that whatever is attempted as an
exercise in foresight will have only entertainment value a few years hence. It may be that
the author's prejudices, fears and wishful thinking also play a part.
46. Abelson, Directed Evolution of Nucleic Acids by Independent Replication and Selection, 249
Sci. 488 (1990); Devlin, Panganiban & Devlin, Random Peptide Libraries: A Source of Specific
Protein Binding Molecules, 249 Sci. 404 (1990); Scott & Smith, Searchingfor Peptide Ligands with
an Epitope Library, 249 Sd. 386 (1990); Tramontano, Janda & Lerner Catalytic Antibodies,
234 Sci. 1566 (1986); Tuerk & Gold, Systematic Evolution of Ligands by Exponential Enrichment:
RNA Ligands to Bacteriophage T4 DNA Polymerase, 249 Sci. 505 (1990).
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seems to be toward ever more predictable methodologies that permit
those skilled in the art to attain alternative functional equivalents. As
the trend progresses, chemical structure will become less important than
function in patenting biological macromolecules. In this respect, bio-
technology patent law may diverge from the precedents of chemical pat-
ent laws.
B. Divergence from Chemical Patent Law
The recent en banc reversal of In re Dillon4 7 comes as a shock to bio-
technology practitioners. The absolute primacy of structural relatedness
as the key to establishing a prima facie case of obviousness seems mis-
placed in a field where structural similarity provides little guidance to
functional properties. The relative unimportance of chemical structure
in the biotechnology field suggests that Dillon should have little rele-
vance. Misapplication of Dillon to biotechnological inventions has the
potential to create considerable mischief.
48
C. Human Genome Project
4 9
The human genome project represents another area of biotechnol-
ogy whose results may affect the development of biotechnology patent
law. The process of mapping and sequencing the human genome is a
47. 919 F.2d 688 (Fed. Cir. 1990). For an in-depth analysis of the en banc rehearing of
Dillon, see Wall & Dituri supra note 27.
48. At present, models of protein structure are not sufficiently developed to predict
accurately three-dimensional configurations of a given sequence. The functional proper-
ties of a given amino acid sequence are almost never predictable from sequence alone.
One can analyze sequence data in probability terms. Homologous sequences are more
likely to have a common function than unrelated sequences. However, a single amino acid
change at a critical locus can nullify the function, or can result in creating a new function.
It is possible, through trial and error mapping experiments, to locate regions of sequence
which tolerate a relatively wide range of sequence variation without affecting function.
Through comparison of common functions in different sequences, certain sequence motifs
are identifiable as associated with specific attributes. However, the level of predictability
afforded by such information is rather crude, analogous to being able to identify which end
of an automobile is the front. While the inventor of a novel protein may be unable to state
from knowledge of its structure alone specifically which among thousands of possible se-
quence variants will retain equivalent function, he can predict with certainty that a very
large number of such variants can easily be made. The same holds true for nucleic acids
where redundant codings for identical amino acid sequences are known. Therefore, until
a comprehensive understanding of structure-function relationships in biological systems is
achieved, structural data are of value primarily to prove novelty and purity, but of little
value to prove obviousness or to limit claim scope. See Wall & Dituri, supra note 27.
49. All living organisms are composed of cells, each no wider than a human hair.
Each of our cells contains the same complement of DNA constituting the human
genome. The DNA sequence of every person's genome is the blueprint for his or
her development from a single cell to a complex, integrated organism that is
composed of more than 10" (10 million million) cells.
NATIONAL RESEARCH COUNCIL COMMrrrEE ON MAPPING AND SEQUENCING THE HUMAN GEN-
OME, MAPPING AND SEQUENCING THE HUMAN GENOME 12 (1988). Currently there is no
single human genome project, instead there are many projects in both the public and
private sectors. Among the objectives of the genome projects are to create maps of human
chromosomes consisting of DNA markers that would permit scientists to locate genes
quickly, and to determine the DNA sequence of a large fraction of the human genome and
that of other organisms. OFFICE OF TECHNOLOGY AsSESSMENT, MAPPING OUR GENES GEN-
OME PROJECTS: How BIG, How FAST 6-7 (1988).
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departure from traditional avenues of scientific inquiry. Segments of
human DNA will be cloned and sequenced without concomitant infor-
mation regarding the function. An enormous amount of position and
sequence data will be added to the databases, often without correlated
information of associated functional properties. 50 The prior art effect of
such data is difficult to predict. It remains an open question whether
Dillon is applicable where the prior art reveals only structure, with no
hint of functional properties. The debate in Dillon over the relative sig-
nificance of "structure" and "properties" as factors in establishing a
prima facie case of obviousness can be expected to continue. The re-
sults, however, may be different in the biotechnology field than in the
chemical field. 5 1
D. Transgenic Animals
The next seventeen years will witness an exponential increase in the
kinds of transgenic animals created. The parameters of patentability for
transgenics are currently unknown. Both genotype (the structure of the
introduced gene and its control elements) and phenotype (the charac-
teristics of the transgenic animal attributable to the introduced gene) are
key features of a transgenic animal that serve to characterize it and to
distinguish it from the prior art. The question of which of these features
is more significant to determine obviousness or to establish a prima facie
case of obviousness is likely to occupy examiners, practitioners, and the
courts for some years. The parallel to the debate over "structure" ver-
sus "properties" in the chemical field is inescapable.
5 2
The problems of patent enforcement for self-replicating products
are likely to be particularly serious for products sold in a mass market.
For patent holders, the prospect of extending transgenic animal tech-
nology to agriculture presents unusual problems. Congress has pro-
posed special legislation that would provide exemptions for farmers,
permitting them to breed and sell patented transgenic animals without
50. Much of the data may be in the form of partial sequences, specifically just enough
sequence at the ends of a cloned segment to allow the same segment to be reisolated from
a library by polymerase chain reaction, using the disclosed sequences as primers. See Ap-
penzeller, Democratizing the DNA Sequence, 247 Sc. 1030 (1990); Roberts, New Game Plan for
Genome Mapping, 245 Sci. 1438 (1989).
51. When doing research, the chemist's attention is generally directed first toward the
structure of a compound and second toward determining its functional properties. In bio-
technology, the reverse is most often the case: research is directed initially toward finding
a compound having a particular function, then secondarily to elucidating its structure.
Within the epistemologies of the two sciences, the relative significance of structure and
properties are quite different. Therefore, the law affecting these two fields of art is likely
to reflect this dichotomy.
52. The kinds of questions which could arise are numerous. If the gene introduced
into mouse A differs only in its promoter from that introduced into mouse B, is A unobvi-
ous in view of B on the ground that the phenotypes of A and B are unpredictably distinct?
If the gene introduced into mouse A yields a characterized phenotype, are rat A, dog A,
horse A, etc., each having the same gene and phenotype obvious in view of mouse A? Will
mouse A', having the same phenotype as mouse A but a slightly different introduced gene,
infringe a claim to mouse A? Is a claim to mouse A overly broad if the gene construct is
recited in terms of equivalent sequences rather than limited to a specific sequence?
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infringement. 53 Underlying such legislation is the fear that effective pat-
ent protection for valuable farm breeding stock might dislocate farm ec-
onomics in socially unfavorable ways. 54 Whether such dislocations
would occur and whether legislation of the sort proposed would have
the effects desired by its sponsors may become a matter of political
debate.
E. Internationalization
In addition to legal issues driven by new science, there are issues
generated by changes in business economics, and by current political
and legal trends. The internationalization of commercial enterprise and
the increasing worldwide interdependence of national economies cre-
ates pressure to develop a more uniform set of national patent laws.
Talks leading to a Patent Harmonization Treaty have been in progress
over the past few years.5 5 The prospects for successful internationaliza-
tion are encouraged by the strength and quality of the European Patent
Convention. 56 The pros and cons for the United States patent system
presented by the Patent Harmonization Treaty have been discussed by
many commentators.5 7 As a practical matter, the international character
of the modern market economy is such that even small businesses must
take into account foreign laws governing patentability and enforce-
ment. 58 The present trend toward increasing harmonization and stand-
ardization of patent laws seems likely to continue.
The nationalistic view of patents as a means to protect local propri-
etary interests is being displaced by a view of patents as a means of pro-
viding world-wide proprietary rights, regardless of the invention's
origin. 59 If the United States adopts a first-to-file system, interferences
53. Transgenic Animal Patent Reform Act, H.R. 4970, 100th Cong., 2d Sess. (1988)
(The statute proposed exemptions for farmers with gross incomes of less than $500,000,
or are single family farmers, or farmers who do not engage in the growing of animals for
sale.).
54. See H.R. REP. No. 888, 100th Cong., 2d Sess., at 72 (1988).
55. See H.R. CON. RES. 354, 101st Cong., 2d Sess., 136 CONG. REC. 94, H5198, E2425
(daily ed. July 20, 1990)(statement of Rep. Porter); Summary of Proceedings at Special Meeting
of the Membership on Harmonizaton on Patent Law, ABA SEc. or PAT., TRADEMARK AND COPY-
RIGHT L., September 9, 10, 1989, at 83 (1990); Interference Issues in a First-to-File World, 18
A.I.P.L.A. Qj. No. 1 (1990).
56. European Patent Convention, art. 93, (1973), reprinted in 78 PAT. & TRADEMARK
REv. 31, 39 (1980).
57. See sources cited supra note 55.
58. Activities which do not bar patentability in the United States, such as public dis-
closure within one year of the patent filing date, can defeat patentability in most other
countries. Small businesses and academic inventors sometimes fail to consider the effects
of such disclosures on patent rights outside the United States, to their increasing detri-
ment. Small businesses increasingly look to foreign markets and academic inventors in-
creasingly seek industrial funding for which world-wide patent rights are a common
consideration. In the absence of a formal harmonization treaty, a kind of street harmoni-
zation exists in which the most restrictive provisions of the laws of each relevant jurisdic-
tion are observed.
59. The trend is uneven, being more pronounced in the more industrialized countries
with strong orientation toward a market economy, weaker in less developed countries
where developing a local industrial-technical base has a high priority.
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will eventually be phased out, although oppositions may come to occupy
a substantial part of the practitioner's docket. Canada has abandoned its
first-to-invent system for a first-to-file system. 60 Although changes oc-
cur with glacial slowness in the international patent arena, the prospect
of an international patent agency, along the lines pioneered by the Euro-
pean Patent Office, providing a unified patent enforceable throughout
the industrialized world is entirely feasible by the end of the next seven-
teen years.
F. Infringement, Equivalence, Claim Interpretation
While issues of patentability have been dominant in the first patent
lifetime, issues of infringement, equivalence and claim interpretation
6 '
may come to dominate the second. Issues of fact, such as whether an
accused organism is identical to a claimed organism, may entail amas-
sing significant amounts of evidence to be resolved. By the end of the
next patent term, the body of case law on equivalence and reverse equiv-
alence is likely to be greatly expanded in breadth and sophistication.
6 2
Indeed, many terms used in biotechnology claims, while definable in
ways that reasonable people would consider clear, may require resort to
an equivalence type of analysis when litigants are involved.
G. Patent Judiciary
The composition of the judiciary may be affected by the growing
number of practitioners and patent examiners that have advanced de-
grees in science. In both the examining corps and the practicing bar,
the number of persons with Ph.D.s or Master's degrees in a biotechnol-
ogy-related discipline 6 3 has increased in response to the technical de-
mands of the subject matter.64 A familiarity with scientific language and
practices ought to be as valuable in court as a familiarity with business
practices and terminology. Both administrative and judicial decision
making may be enhanced. The infusion of a greater degree of scientific
knowledge into decision making, both in patent law and in general law,
will be a side benefit of the growth of biotechnology.
60. The Patent Act, CAN. REV. STAT. ch. p-4, § 27 (1985), amended by ch. 33, § 8 (3rd
Supp. 1987) (As a result of this amendment the United States and the Philippines are the
only remaining countries with a first-to-invent system.).
61. See Graver Tank & Mfg. Co. v. Linde Air Prods. Co., 339 U.S. 605, 608
(1950) ("[A] patentee may invoke this doctrine [of equivalents] to proceed against the pro-
ducer of a device 'if it performs substantially the same function in substantially the same
way to obtain the same result.' ").
62. See Genentech, Inc. v. The Wellcome Found. Ltd., 14 U.S.P.Q.2d (BNA) 1363 (D.
Del. 1990)(Denying summary judgment in a biotechnology patent infringement action
brought by Genentech against Wellcome, the judge found a triable issue of fact concern-
ing whether the patented compound and infringing compound performed in substantially
the same way.).
63. Biotechnology-related disciplines include physics, chemistry, microbiology, bio-
chemistry, genetics or molecular biology and physiology.
64. That some of these will eventually complete the transit from lab bench to judicial
bench should be a healthy trend provided their legal qualifications are the primary selec-
tion criteria.
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IV. CONCLUDING SUMMARY
The existing precedents, based primarily in the chemistry field,
served adequately during the early development of biotechnology. Ma-
jor threshold questions of patentability, relative to living organisms and
products of nature, are now largely resolved. The courts now accept
products of biotechnology as patentable subject matter, subject to the
same statutory criteria of novelty, unobviousness, description and en-
ablement as inventions in other fields. Applying the statutory criteria to
the facts of biotechnology inventions is an ongoing process, whose out-
lines in the .case law are only beginning to take shape. As biotechnology
patent practice matures, it is being viewed less as a direct descendant of
chemical practice than as a cousin. The body of biotechnology prece-
dents is expected to take on a more individualistic character separate
from chemical practice and drawing from precedents in other arts as
well.
The future will be characterized by further definition of a body of
biotechnology case law, which in turn will be affected by new technolo-
gies that further accent differences between biotechnology practice and
chemical practice. General trends toward internationalization of busi-
ness and harmonization of patent laws can be expected to bring about
more uniform treatment of biotechnology in patent systems around the
world.
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